bioRxiv Science⌕ Search

Biology subjects

Rehani, P.

Publications and source records attributed to Rehani, P..

2 recordsLinked to original sources

Autofluorescence lifetime imaging classifies human lymphocyte activation and subtype

New non-destructive tools are needed to reliably assess lymphocyte function for immune profiling and adoptive cell therapy. Optical metabolic imaging (OMI) is a label-free method that measures the autofluorescence intensity and lifetime of metabolic cofactors NAD(P)H and FAD to quantify metabolism at a single-cell level. Here, we investigate whether OMI can resolve metabolic changes between human quiescent versus IL4/CD40 activated B cells and IL12/IL15/IL18 activated memory-like NK cells. We found that quiescent B and NK cells were more oxidized compared to activated cells. Additionally, the NAD(P)H mean fluorescence lifetime decreased and the fraction of unbound NAD(P)H increased in the activated B and NK cells compared to quiescent cells. Machine learning classified B cells and NK cells according to activation state (CD69+) based on OMI parameters with up to 93.4% and 92.6% accuracy, respectively. Leveraging our previously published OMI data from activated and quiescent T cells, we found that the NAD(P)H mean fluorescence lifetime increased in NK cells compared to T cells, and further increased in B cells compared to NK cells. Random forest models based on OMI classified lymphocytes according to subtype (B, NK, T cell) with 97.8% accuracy, and according to activation state (quiescent or activated) and subtype (B, NK, T cell) with 90.0% accuracy. Our results show that autofluorescence lifetime imaging can accurately assess lymphocyte activation and subtype in a label-free, non-destructive manner. TeaserLabel-free optical imaging can assess the metabolic state of lymphocytes on a single-cell level in a touch-free system.

bioengineering↗

Integrative multi-omics analyses identify cell-type disease genes and regulatory networks across schizophrenia and Alzheimer's disease

Understanding cell-type-specific gene regulatory mechanisms from genetic variants to diseases remains challenging. To address this, we developed an open-source computational pipeline, scGRNom, to predict the cell-type disease genes and regulatory networks from multi-omics data, including cell-type chromatin interactions, epigenomics, and single-cell transcriptomics. With applications to Schizophrenia and Alzheimers Disease, our predicted cell-type regulatory networks link transcription factors and enhancers to disease genes for excitatory and inhibitory neurons, microglia, and oligodendrocytes. The enrichments of cell-type disease genes reveal cross-disease and disease-specific functions and pathways. Finally, machine learning analysis found that cell-type disease genes shared by diseases have improved clinical phenotype predictions.

neuroscience↗